2. Cancer
  3. Cancer Metabolism and Metastasis

Cancer Metabolism and Metastasis

Metabolic abnormalities are a major feature of cancer, such as increased substance anabolic pathways and aerobic glycolysis. Cancer metabolism shows flexibility and plasticity, which are crucial for the survival and growth of cancer cells. Cancer metastasis is completed in five steps i.e. invasion, dissemination, circulating tumor cells, colonization, and secondary tumor formation. Recently, metabolic adaptation mechanism of cancer metastasis has been proposed to reveal the extensive relationship between cancer metabolism and cancer metastasis. Metastasizing cancer cells selectively and dynamically adapt their metabolism during the complex multistep cascade.

Many nutrients can promote metabolite plasticity during metastasis. For example, lactic acid and pyruvate are the nutrients that cells can directly absorb from the environment; many cancer cells take up glutamine, which contributes to non-essential amino acid as well as nucleotide synthesis through nitrogen or carbon metabolism. Inhibiting the function of key enzymes in metabolic pathways can in turn inhibit the proliferation of cancer cells. For example, lactate dehydrogenase A or B (LDH-A or -B) knockdown can inhibit breast cancer cell motility in vitro. Oncogenic signaling pathways, such as Myc, phosphoinositide 3-kinase (PI3K)/AKT pathway, MAPK/ERK pathway, LKB1/AMPK pathway and Hippo pathways, mediate metabolic gene expression and increase metabolic enzyme activities.

Cancer Metabolism and Metastasis Related Products (42796):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100620R
    RPR121056 (Standard) 181467-56-1
    RPR121056 (Standard) is the analytical standard of RPR121056. This product is intended for research and analytical applications. RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1].
    RPR121056 (Standard)
  • HY-N10352
    4-epi-Withaferin A 1214886-27-7
    4-epi-Withaferin A (compound 28) is the analogue of Withaferin A. 4-epi-Withaferin A enhances cytotoxicity and cytoprotective heat-shock-inducing activity (HSA). 4-epi-Withaferin A has the potential for the research of protein aggregation-associated diseases by stimulating cellular defense mechanisms.
    4-epi-Withaferin A
  • HY-122593
    PI3Kδ-IN-5 2088525-31-7 99.62%
    PI3Kδ-IN-5 (compound 7n) is a highly potent and selective inhibitor of PI3Kδ with an IC50 of 0.9 nM.
    PI3Kδ-IN-5
  • HY-N10355
    27-TBDMS-4-Dehydrowithaferin A 1214886-31-3
    27-TBDMS-4-Dehydrowithaferin A, a withaferin A derivative, exhibits potent antiproliferative effects on the tumor cells.27-TBDMS-4-Dehydrowithaferin A induces tumor cells apoptosis. 27-TBDMS-4-Dehydrowithaferin A is a anticancer agent.
    27-TBDMS-4-Dehydrowithaferin A
  • HY-123410
    KM-233 628263-22-9
    KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research.
    KM-233
  • HY-N10350
    2,3-Dihydro-3-methoxywithaferin A 21902-96-5
    2,3-Dihydro-3-methoxywithaferin A is an analogue of 2,3-dihydrowithaferin-A. 2,3-Dihydro-3-methoxywithaferin A inhibits proiiferation of P388 cells[1].
    2,3-Dihydro-3-methoxywithaferin A
  • HY-51424S
    PLX-4720-d7 1304096-50-1
    PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of B-RafV600E with an IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf[1][2].
    PLX-4720-d<sub>7</sub>
  • HY-N10354
    27-Methyl withaferin A 1777780-93-4
    27-Methyl withaferin A (comppund 26) is an apoptosis inducer with anticancer effects. 27-Methyl withaferin A shows antiproliferative effects against HeLa, A-549 and MCF-7 human tumor cell lines with IC50 values of 3.2 μM, 4.2 μM and 1.4 μM, respectively.
    27-Methyl withaferin A
  • HY-18310
    NIBR-17 944396-88-7
    NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.
    NIBR-17
  • HY-13725AR
    Pirarubicin Hydrochloride (Standard) 95343-20-7
    Pirarubicin (Hydrochloride) (Standard) is the analytical standard of Pirarubicin (Hydrochloride). This product is intended for research and analytical applications. Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.
    Pirarubicin Hydrochloride (Standard)
  • HY-N10351
    27-O-(tert-Butyldimethylsilyl)withaferin A 1392820-18-6
    27-O-(tert-Butyldimethylsilyl)withaferin A (compound 9a), a natural withanolide, is an apoptosis inducer. 27-O-(tert-Butyldimethylsilyl)withaferin A shows antiproliferative activity against HeLa, A-549 and MCF-7 human cancer cell lines, and against normal Vero cells.
    27-O-(tert-Butyldimethylsilyl)withaferin A
  • HY-D1468
    Phototherapeutic agent-1 2555045-67-3
    Phototherapeutic agent-1 is a multi-modal light diagnosis agent with aggregation-induced emission properties. have certain Phototherapeutic agent-1 has certain reactive oxygen species (ROS) generation capacity in illumination condition. Phototherapeutic agent-1 can effectively kill cancer cells and tumor tissue.
    Phototherapeutic agent-1
  • HY-107439
    Thalidomide-O-amido-C8-NH2 1950635-15-0
    Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
    Thalidomide-O-amido-C8-NH2
  • HY-13562S
    Banoxantrone-d12 1562067-05-3
    Banoxantrone-d12 is the deuterium labeled banoxantrone. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
    Banoxantrone-d<sub>12</sub>
  • HY-13562AS
    Banoxantrone-d12 dihydrochloride 1562066-98-1
    Banoxantrone-d12 (dihydrochloride) is the deuterium labeled Banoxantrone dihydrochloride. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
    Banoxantrone-d<sub>12</sub> dihydrochloride
  • HY-100863
    BRCA1-IN-1 1622262-74-1
    BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively.
    BRCA1-IN-1
  • HY-103610
    4,4'-Dimethoxybenzil 1226-42-2 99.83%
    4,4'-Dimethoxybenzil is a human intestinal carboxyl esterase (hiCE) inhibitor with Ki of 70 nM.
    4,4'-Dimethoxybenzil
  • HY-U00304
    Aurora B inhibitor 1 937276-52-3
    Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
    Aurora B inhibitor 1
  • HY-15594
    Phen-DC3 942936-75-6
    Phen-DC3 is a G-quadruplex (G4) specific ligand which can inhibit FANCJ and DinG helicases with IC50s of 65±6 and 50±10 nM, respectively.
    Phen-DC3
  • HY-P0300
    Bak BH3 300349-67-1
    Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of Bcl-xL in cells.
    Bak BH3